Anixa Biosciences Receives Additional US Patent for CAR-T Technology, Extending Protection to 2045

Anixa Biosciences has received a US patent for its CAR-T technology from the US Patent and Trademark Office, extending protection to 2045. This technology is used in cancer immunotherapy, which involves using genetically modified T cells to target and destroy cancer cells. The patent covers Anixa's CAR-T technology, which is a significant development for the company.

Anixa Biosciences (NASDAQ: ANIX) has received a significant boost as the United States Patent and Trademark Office (USPTO) has issued a U.S. patent covering its chimeric antigen receptor-T cell (CAR-T) technology. This patent, which extends protection to 2045, encompasses core methods and compositions fundamental to Anixa's CAR-T approach. The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences.

The CAR-T technology, currently in clinical trials at Moffitt Cancer Center for the treatment of recurrent ovarian cancer, represents a significant advancement in cancer immunotherapy. This approach involves using genetically modified T cells to target and destroy cancer cells, offering a promising avenue for personalized cancer treatment.

The patent issuance comes at a crucial time for Anixa Biosciences, which is already seeing positive market reception. The company's shares were up more than 3% in premarket trading following the announcement, reflecting investor confidence in the company's technological advancements and clinical progress.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) also recently made headlines with the FDA approval of the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). This approval marks a significant milestone in the development of breakthrough immunomodulation therapies for an unmet medical need.

These developments underscore the ongoing innovation and progress in the biotechnology sector, particularly in the areas of cancer immunotherapy and neuroinflammation treatment.

References:
[1] https://seekingalpha.com/news/4483856-anixa-biosciences-announces-issuance-of-additional-us-patent-for-car-t-technology
[2] https://www.biospace.com/press-releases/fda-approves-tiziana-life-sciences-phase-2-ind-for-multiple-system-atrophy